Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,176 across all filing types
Latest filing 2024-04-30 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges (BSE and NSE) regarding a regulatory order received from a tax authority (Gujarat GST Authority) imposing a penalty. It references compliance with SEBI Listing Regulations and provides details of the order, including the nature of the penalty and the company's response. The document is short (3952 characters) and serves as an announcement of a regulatory event rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or audit information. It is not a report itself but a regulatory disclosure about a legal/regulatory matter. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-04-30 English
Intimation regarding loss of share certificate by the shareholder.
Regulatory Filings Classification · 95% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. It details the loss of share certificates and the stop transfer request related to those certificates. The document is addressed to stock exchanges and signed by the company secretary. It is a regulatory compliance filing related to share certificate handling and does not contain financial data, management discussion, or report content. The document length is short (2976 characters) and is a formal compliance certificate rather than a report or announcement of a report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2024-04-25 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. It details the loss of share certificates and requests stop transfer, addressed to stock exchanges. It is a regulatory compliance communication related to share certificate handling, not a financial report, earnings release, or management information. The document length is short (2982 characters) and it is a formal regulatory filing rather than a report or announcement of a report. Therefore, it fits best under Regulatory Filings (RNS).
2024-04-25 English
Lupin receives EIR from U.S. FDA for its Aurangabad Manufacturing Plant.
Regulatory Filings Classification · 95% confidence The document is a press release dated April 23, 2024, announcing that Lupin Limited has received the Establishment Inspection Report (EIR) from the U.S. FDA for its Aurangabad manufacturing facility. It mentions the inspection dates and the classification outcome (Voluntary Action Indicated). The document is a disclosure pursuant to Regulation 30 of SEBI Listing Regulations, which typically requires companies to inform stock exchanges about material events. The document is short (4099 characters) and serves as an announcement of receipt of a regulatory inspection report rather than the report itself or detailed financial data. It does not contain financial statements, management discussion, or detailed audit information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and disclosures that do not fit other specific categories.
2024-04-23 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated April 23, 2024, announcing that Lupin Limited has received the Establishment Inspection Report (EIR) from the U.S. FDA for its Aurangabad manufacturing facility. The text is a disclosure pursuant to Regulation 30 of SEBI Listing Regulations, which typically requires timely public disclosure of material events. The document is short (4099 characters) and primarily serves as an announcement of receipt of a regulatory inspection report, not the report itself. There are no financial statements, detailed analysis, or comprehensive report content. Therefore, this is a regulatory announcement about a material event, fitting best under Regulatory Filings (RNS) as a general regulatory announcement and disclosure.
2024-04-23 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2024-04-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.